Brokerages predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will post sales of $44.50 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with the highest sales estimate coming in at $45.00 million and the lowest estimate coming in at $43.80 million. Vanda Pharmaceuticals reported sales of $38.48 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.6%. The company is expected to issue its next earnings results on Wednesday, November 1st.

On average, analysts expect that Vanda Pharmaceuticals will report full-year sales of $44.50 million for the current year, with estimates ranging from $169.40 million to $172.00 million. For the next financial year, analysts anticipate that the business will report sales of $206.43 million per share, with estimates ranging from $194.00 million to $218.20 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The firm had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. During the same period in the previous year, the firm earned $0.01 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis.

VNDA has been the subject of a number of recent analyst reports. Piper Jaffray Companies reiterated an “overweight” rating and set a $23.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, June 27th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. HC Wainwright initiated coverage on Vanda Pharmaceuticals in a report on Friday, May 26th. They set a “buy” rating and a $18.00 price target for the company. Jefferies Group LLC reiterated a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Finally, Zacks Investment Research upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $21.63.

Several institutional investors and hedge funds have recently modified their holdings of VNDA. Legal & General Group Plc grew its stake in shares of Vanda Pharmaceuticals by 37.4% in the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,022 shares during the period. Virginia Retirement Systems ET AL acquired a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at about $193,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at about $196,000. Kopp Investment Advisors LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at about $196,000. Finally, Airain ltd grew its stake in shares of Vanda Pharmaceuticals by 50.8% in the 1st quarter. Airain ltd now owns 21,415 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 7,213 shares during the period. Institutional investors own 86.49% of the company’s stock.

TRADEMARK VIOLATION WARNING: “$44.50 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/22/44-50-million-in-sales-expected-for-vanda-pharmaceuticals-inc-vnda-this-quarter-2.html.

Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 18.85 on Friday. The firm’s market capitalization is $845.57 million. Vanda Pharmaceuticals has a 1-year low of $12.70 and a 1-year high of $18.99. The firm has a 50-day moving average price of $16.57 and a 200-day moving average price of $15.25.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.